Core Insights - The company announced positive immunogenicity and safety data for its core product LZ901 in a head-to-head comparison with the HZ/su vaccine in adults aged 50 and above [1] Group 1: Study Details - A randomized, active-controlled, non-inferiority trial was conducted, enrolling 301 healthy adults aged 50 and above, with at least 291 receiving two doses of either LZ901 or HZ/su vaccine [1] - Results indicated that LZ901 induced superior cellular immunogenicity and demonstrated better safety compared to the HZ/su vaccine in the target demographic [1] Group 2: Product Information - LZ901 is a recombinant shingles vaccine developed by the company, aimed at preventing shingles and related complications in adults aged 40 and above [1] - The biological product license application for LZ901 has been accepted by the National Medical Products Administration of the People's Republic of China and is currently under review [1]